Jupiter Topco LLC Makes New $1.05 Billion Investment in BridgeBio Pharma, Inc. $BBIO

Posted by George Bondi on Aug 26th, 2026

Jupiter Topco LLC purchased a new position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 14,110,278 shares of the company’s stock, valued at approximately $1,050,762,000. Jupiter Topco LLC owned approximately 7.22% of BridgeBio Pharma as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Brooklands Fund Management Ltd bought a new position in shares of BridgeBio Pharma in the fourth quarter valued at approximately $210,348,000. Price T Rowe Associates Inc. MD lifted its stake in shares of BridgeBio Pharma by 144.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,828,746 shares of the company’s stock worth $292,862,000 after buying an additional 2,261,181 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in shares of BridgeBio Pharma by 25.8% during the 4th quarter. Janus Henderson Group PLC now owns 11,000,457 shares of the company’s stock worth $841,349,000 after buying an additional 2,259,378 shares during the period. The Manufacturers Life Insurance Company acquired a new position in BridgeBio Pharma in the 2nd quarter valued at $145,663,000. Finally, Norges Bank acquired a new position in BridgeBio Pharma in the 4th quarter valued at $116,802,000. Institutional investors and hedge funds own 99.85% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on BBIO. Citigroup boosted their target price on shares of BridgeBio Pharma from $82.00 to $93.00 and gave the stock a “neutral” rating in a research report on Thursday, July 16th. Bank of America lifted their price objective on BridgeBio Pharma from $101.00 to $104.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. Wells Fargo & Company boosted their price objective on BridgeBio Pharma from $98.00 to $102.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 11th. JPMorgan Chase & Co. increased their target price on BridgeBio Pharma from $100.00 to $111.00 and gave the company an “overweight” rating in a research note on Wednesday, August 12th. Finally, Raymond James Financial lowered BridgeBio Pharma from an “outperform” rating to a “market perform” rating in a report on Tuesday, May 26th. Twenty analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, BridgeBio Pharma currently has an average rating of “Moderate Buy” and a consensus target price of $100.79.

Read Our Latest Stock Report on BBIO

BridgeBio Pharma Trading Down 0.8%

Shares of NASDAQ:BBIO opened at $80.40 on Wednesday. BridgeBio Pharma, Inc. has a 1-year low of $47.26 and a 1-year high of $93.42. The firm has a market capitalization of $15.72 billion, a PE ratio of -22.52 and a beta of 0.96. The business’s 50 day moving average is $79.38 and its 200-day moving average is $73.34.

BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) last issued its earnings results on Monday, August 10th. The company reported ($0.78) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.20). The company had revenue of $243.68 million during the quarter, compared to analyst estimates of $220.91 million. The company’s quarterly revenue was up 120.4% compared to the same quarter last year. During the same period last year, the firm earned ($0.95) EPS. On average, sell-side analysts predict that BridgeBio Pharma, Inc. will post -2.62 EPS for the current year.

Insider Buying and Selling at BridgeBio Pharma

In other BridgeBio Pharma news, Director Jennifer E. Cook sold 148,589 shares of BridgeBio Pharma stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $88.54, for a total transaction of $13,156,070.06. Following the sale, the director directly owned 8,383 shares of the company’s stock, valued at approximately $742,230.82. The trade was a 94.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Hannah Valantine sold 2,808 shares of the business’s stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $68.00, for a total value of $190,944.00. Following the completion of the sale, the director directly owned 11,455 shares in the company, valued at approximately $778,940. This represents a 19.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 387,343 shares of company stock worth $30,289,400. Corporate insiders own 14.23% of the company’s stock.

BridgeBio Pharma Profile

(Free Report)

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.